Translumina Names Appointments to Senior Leadership Posts

October 10, 2022—Translumina, a developer and manufacturer of cardiovascular medical devices, implants, and access products based in New Delhi, India, and Hechingen, Germany, announced the appointment of Indranil Mukherjee as Group Chief Executive Officer and Armin Kiser as Managing Director and Chief Operating Officer for the company’s Europe operations.

Previously, Mr. Mukherjee was Managing Director at B. Braun Group in India. Mr. Armin was the Chief Operating Officer at Biedermann Motech, a developer and manufacturer of implants and instruments for spinal and extremity surgery; before that, he was Site Leader for Edwards Lifesciences’ manufacturing facility in Switzerland.

Mr. Mukherjee commented in the company’s press release, “Translumina presents a unique opportunity to build a leading global med tech company with a strong innovation culture and deep-seated roots in both India and Germany. I look forward to driving the next chapter of growth for the business that will involve bringing a further set of breakthrough technologies to patients around the world, together with a passionate and committed team at Translumina and supportive founders and shareholders.”

Mr. Armin added, "Translumina presents a fascinating opportunity and intricate challenges. The company’s audacious culture, growth mindset, and committed team is a great fit with my values and aspirations, and I look forward to building on our strong R&D and manufacturing foundation in Germany.”

In April 2022, Translumina announced the launch of the Vivo Isar dual-drug polymer-free coated stent in various international markets, including Europe.

Gurmit Singh Chugh, Chairman and Cofounder of Translumina, stated, “It’s amazing to see how Translumina, which I cofounded with Punita Sharma in 2010, has achieved a marquee position in the interventional cardiovascular devices space in India and international markets. In addition to creating the widely acclaimed drug-eluting stent technologies, which represent the highest standards of clinical evidence, we are now entering newer segments of specialty balloons and structural heart with innovative transcatheter solutions for mitral, aortic, and tricuspid valves. With Indranil and Armin complementing the existing leadership of Paritosh Arora, India Managing Director, and Kewal Jindal, Group Chief Financial Officer, we are all set to scale up and establish Translumina globally as an industry standard in innovation, quality, and clinical evidence in [the] health care space within next 2 years.”